Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Bone Marrow Transplant Plus Cyclophosphamide and Total-Body Irradiation in Treating Patients With Hematologic Cancer

This study has been completed.
Information provided by:
Temple University Identifier:
First received: November 1, 1999
Last updated: September 30, 2010
Last verified: September 2010

November 1, 1999
September 30, 2010
August 1996
December 2003   (Final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00002809 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Bone Marrow Transplant Plus Cyclophosphamide and Total-Body Irradiation in Treating Patients With Hematologic Cancer
Unrelated Bone Marrow Transplantation With Cyclophosphamide and Total Body Irradiation For Hematologic Malignancies and Bone Marrow Failure States

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells. Combining chemotherapy and radiation therapy together with bone marrow transplant may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells.

PURPOSE: This phase II trial is studying how well giving bone marrow transplant from an unrelated donor together with cyclophosphamide and total-body irradiation works in treating patients with hematologic cancer.


  • Study the curative potential of high-dose cyclophosphamide and total-body irradiation followed by rescue with bone marrow from volunteer HLA-matched donors in patients with a variety of hematologic malignancies and bone marrow failure states.
  • Study the toxic effects associated with matched unrelated bone marrow transplantation in this patient population.
  • Participate in collaborative research studies with the National Marrow Donor Program.

OUTLINE: All patients receive myeloablative therapy with high-dose cyclophosphamide and total body irradiation over 4 days; patients with severe aplastic anemia also receive antithymocyte globulin. Patients then undergo allogeneic bone marrow transplantation. Filgrastim (G-CSF) is given after transplant to accelerate engraftment. Sargramostim (GM-CSF) may be given in case of graft failure.

All patients receive graft-versus-host-disease (GVHD) prophylaxis with tacrolimus, methotrexate, and gamma globulin. Established GVHD is treated with corticosteroids and, as necessary, antithymocyte globulin.

Patients are followed at 100 days, 6 months, and 1 year after transplant, then annually thereafter.

PROJECTED ACCRUAL: A total of 10 patients per year will be accrued for this study over 5 years.

Phase 2
Masking: Open Label
Primary Purpose: Treatment
  • Leukemia
  • Myelodysplastic Syndromes
  • Myelodysplastic/Myeloproliferative Diseases
  • Biological: anti-thymocyte globulin
  • Biological: filgrastim
  • Biological: sargramostim
  • Biological: therapeutic immune globulin
  • Drug: cyclophosphamide
  • Drug: methotrexate
  • Drug: tacrolimus
  • Procedure: allogeneic bone marrow transplantation
  • Radiation: radiation therapy
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
December 2003
December 2003   (Final data collection date for primary outcome measure)


  • One of the following hematologic malignancies/disorders:

    • Acute lymphoblastic leukemia

      • In second or subsequent complete remission (CR)
      • In first CR with high-risk features (e.g., Philadelphia chromosome-positive)
      • In first relapse and failed conventional salvage therapy
    • Acute myelogenous leukemia (AML)

      • In second or subsequent CR
      • In early first relapse
      • In full first relapse and failed conventional salvage therapy
      • In first CR with high-risk features, e.g., trisomy 8 or FAB 6/7

        • Standard-risk AML offered conventional-dose consolidation chemotherapy or autologous bone marrow transplantation
    • Chronic myelogenous leukemia in chronic, accelerated, or second chronic phase

      • No blast crisis
    • Severe aplastic anemia that has failed at least 1 course of immunosuppressive therapy
    • Paroxysmal nocturnal hemoglobinuria with high-risk features (e.g., disseminated intravascular coagulation, thrombotic events)
    • Myelodysplastic syndrome, i.e.:

      • Symptomatic, transfusion-dependent refractory anemia with excess blasts
      • (RAEB) or RAEB in transformation
    • Secondary leukemia in CR following conventional-dose induction chemotherapy
  • Unrelated marrow donor available who is 8 out of 10-, 9 out of 10-, or 10 out of 10-antigen serologically HLA-matched at A, B, C, DRb, and DQB loci by molecular typing
  • No CNS malignancy



  • 17 to 60

Performance status:

  • Karnofsky 70-100%

Life expectancy:

  • No reduction due to other serious illness


  • Not specified


  • Bilirubin less than 3 mg/dL
  • AST/ALT no greater than twice normal


  • Creatinine no greater than 2.0 mg/dL
  • Creatinine clearance greater than 60 mL/min


  • Left ventricular ejection fraction at least 45%
  • No severe hypertension


  • DLCO, FEV_1, and FVC at least 50%


  • HIV negative
  • No active infection at time of transplant
  • No advanced diabetes
  • No significant neurologic deficit
  • No active drug or substance abuse
  • No emotional disorders
  • Able to participate in frequent medical care for at least 1-2 years
  • Willing to comply with National Marrow Donor Program policies


Biologic therapy

  • See Disease Characteristics


  • See Disease Characteristics

Endocrine therapy

  • Not specified


  • Not specified


  • Not specified
Sexes Eligible for Study: All
17 Years to 60 Years   (Child, Adult)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Not Provided
Not Provided
Temple University Bone Marrow Transplant Program, Temple University Health Systems
Temple University
Not Provided
Study Chair: Kenneth F. Mangan, MD, FACP Fox Chase Cancer Center
Temple University
September 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP